Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

Journal of Clinical Medicine 2026 Open access

Read full text
Authors: Burak Paçacı, Erkam Kocaaslan, Ahmet Demirel, Fırat Akagündüz, Mustafa Alperen Tunç, Yeşim Ağyol, Ali Kaan Güren, Abdussamed Çelebi, Selver Işık, Ezgi Çoban, Nargiz Majidova, Nadiye Sever
+12 more Işık Paçacı, Buket Erkan Ozmarasali, Adem Deligönül, Ali Fuat Gürbüz, Melek Karakurt Eryılmaz, Şüheda Ataş İpek, Nisanur Sarıyar Busery, Emre Yılmaz, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek, Nazım Can Demircan
DOI: 10.3390/jcm15020890
Cited by: 1
References: 28

Abstract

Background: Mucosal malignant melanoma (MMM) is a rare and aggressive malignancy with a dismal prognosis. While the Systemic Immune-Inflammation Index (SII) has emerged as a prognostic marker in various solid tumors, its specific value in MMM remains undefined. This study investigated the association between pretreatment SII and overall survival (OS) in patients with MMM. Methods: We retrospectively analyzed 106 adults with histologically confirmed MMM treated at six oncology centers in Turkey between 2005 and 2025. The baseline SII was calculated as platelet × neutrophil/lymphocyte counts obtained before definitive treatment. A receiver operating characteristic (ROC) analysis identified an optimal SII cutoff of 776 for overall survival (OS), defining low (

Fields of Study & Subjects

Inflammatory Biomarkers in Disease Prognosis Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis

Publication details

Journal / source
Journal of Clinical Medicine
Publisher
MDPI AG
Volume
15
Issue
2
Pages
890–890
Publication date
22 January 2026
Language
EN